Chronic Metabolic Disease Drug - Global and China Top Players Market Share and Ranking 2023
This report studies and analyses global Chronic Metabolic Disease Drug status and future trends, helps the client to determine the Chronic Metabolic Disease Drug market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Chronic Metabolic Disease Drug, and provides market size (in K Units & US$ million) and Year-over-Year growth, considering 2022 as the base year.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
To assess the competitive environment within the market including supplier revenue, market share, and company profiles.
Highlights
(1) Global Chronic Metabolic Disease Drug market size, history data 2018-2023, and forecast data 2024 -2029, (US$ million) & (K Units)
(2) Global Chronic Metabolic Disease Drug sales, revenue, price by company, market share and industry ranking 2018-2023, (US$ million) & (K Units)
(3) China Chronic Metabolic Disease Drug sales, revenue, price by company, market share and industry ranking 2018-2023, (US$ million) & (K Units)
(4) Global Chronic Metabolic Disease Drug key consuming regions, consumption quantity, consumption value and demand structure
(5) Global Chronic Metabolic Disease Drug key producing regions, capacity, production, and year over year growth
(6) Chronic Metabolic Disease Drug industry chains, upstream, midstream and downstream
According to Latest Research, the global market for Chronic Metabolic Disease Drug should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By country, China accounted for percent of the global market last year and China’s market share increased from percent to percent. China Chronic Metabolic Disease Drug market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029. The United States Chronic Metabolic Disease Drug market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
By segment, Hospital grew percent to account for percent of the total market sales, and Clinic grew percent.
Key Players Driving the Market:
Novartis
Daiichi Sankyo
Actelion Pharmaceuticals
Boehringer Ingelheim
Eli Lilly
Fresenius Kabi
Torrent Labs
Pfizer
Novo Nordisk
AstraZeneca plc
Regeneron Pharmaceuticals
GlaxoSmithKline plc
Merck & Co. Inc
By Product Type, the market is primarily segmented into:
Hypertension Drug
Hyperlipidemia Drug
High Blood Sugar Drug
High Uric Acid Drug
By Applications, the market is segmented into:
Hospital
Clinic
Others
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
The Report Consists of The Following Points:
Chapter 1: to describe Chronic Metabolic Disease Drug product scope, global sales quantity, value and average price, China sales quantity, value and average price, development opportunities, challenges, trends, and policies.
Chapter 2: Global Chronic Metabolic Disease Drug market share and ranking of major manufacturers, sales quantity, revenue, average price, 2018-2023
Chapter 3: China Chronic Metabolic Disease Drug market share and ranking of major manufacturers, sales quantity, revenue, average price, 2018-2023
Chapter 4: Global key producing regions of Chronic Metabolic Disease Drug, percent & CAGR, 2018-2029
Chapter 5: Chronic Metabolic Disease Drug industry chain, upstream, medium-stream, and downstream.
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2018-2029
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2018-2029
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2018-2029
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2018-2029
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin.
Chapter 11: Conclusions
1 Market Overview
1.1 Chronic Metabolic Disease Drug Definition
1.2 Global Chronic Metabolic Disease Drug Market Size and Forecast
1.2.1 By Consumption Value, Global Chronic Metabolic Disease Drug Market Size，2018-2029
1.2.2 By Sales Quantity, Global Chronic Metabolic Disease Drug Market Size，2018-2029
1.2.3 Global Chronic Metabolic Disease Drug Average Selling Price (ASP)，2018-2029
1.3 China Chronic Metabolic Disease Drug Market Size and Forecast
1.3.1 By Consumption Value, China Chronic Metabolic Disease Drug Market Size，2018-2029
1.3.2 By Sales Quantity, China Chronic Metabolic Disease Drug Market Size，2018-2029
1.3.3 China Chronic Metabolic Disease Drug Average Selling Price (ASP)， 2018-2029
1.4 Share of China Chronic Metabolic Disease Drug Market with Respect to the Global Market
1.4.1 By Consumption Value, China Chronic Metabolic Disease Drug Market Share in Global, 2018-2029
1.4.2 By Sales Quantity, China Chronic Metabolic Disease Drug Market Share in Global, 2018-2029
1.4.3 Chronic Metabolic Disease Drug Market Size: China VS Global, 2018-2029
1.5 Chronic Metabolic Disease Drug Market Dynamics
1.5.1 Chronic Metabolic Disease Drug Market Drivers
1.5.2 Chronic Metabolic Disease Drug Market Restraints
1.5.3 Chronic Metabolic Disease Drug Industry Trends
1.5.4 Chronic Metabolic Disease Drug Industry Policy
2 Global Leading Manufacturers and Market Share
2.1 By Revenue of Chronic Metabolic Disease Drug, Global Market Share by Company, 2018-2023
2.2 By Sales Quantity of Chronic Metabolic Disease Drug, Global Market Share by Company, 2018-2023
2.3 Chronic Metabolic Disease Drug Average Selling Price (ASP) by Company, 2018-2023
2.4 Global Chronic Metabolic Disease Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global Chronic Metabolic Disease Drug Concentration Ratio
2.6 Global Chronic Metabolic Disease Drug Mergers & Acquisitions, Expansion Plans
2.7 Global Chronic Metabolic Disease Drug Manufacturers Product Type
2.8 Head Office and Chronic Metabolic Disease Drug Production Site of Key Manufacturer
2.9 Chronic Metabolic Disease Drug Capacity of Major Manufacturers and Future Plan
3 China Leading Manufacturers and Market Share
3.1 By Revenue of Chronic Metabolic Disease Drug, China Market Share by Company, 2018-2023
3.2 By Sales Quantity of Chronic Metabolic Disease Drug, China Market Share by Company, 2018-2023
3.3 China Chronic Metabolic Disease Drug Participants, Market Position (Tier 1, Tier 2, and Tier 3)
4 Global Producing Regions
4.1 Global Chronic Metabolic Disease Drug Capacity, Output and Capacity Utilization, 2018-2029
4.2 Global Chronic Metabolic Disease Drug Capacity by Region
4.3 Global Chronic Metabolic Disease Drug Production & Forecast by Region, 2018 VS 2022 VS 2029
4.4 Global Chronic Metabolic Disease Drug Production by Region, 2018-2029
4.5 Global Chronic Metabolic Disease Drug Production Market Share & Forecast by Region, 2018-2029
5 Industry Chain Analysis
5.1 Chronic Metabolic Disease Drug Industry Chain
5.2 Chronic Metabolic Disease Drug Upstream Analysis
5.2.1 Chronic Metabolic Disease Drug Core Raw Materials
5.2.2 Main Manufacturers of Chronic Metabolic Disease Drug Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 Chronic Metabolic Disease Drug Production Mode
5.6 Chronic Metabolic Disease Drug Procurement Model
5.7 Chronic Metabolic Disease Drug Industry Sales Model and Sales Channels
5.7.1 Chronic Metabolic Disease Drug Sales Model
5.7.2 Chronic Metabolic Disease Drug Typical Distributors
6 Sights by Type
6.1 Chronic Metabolic Disease Drug Classification
6.1.1 Hypertension Drug
6.1.2 Hyperlipidemia Drug
6.1.3 High Blood Sugar Drug
6.1.4 High Uric Acid Drug
6.2 By Type, Global Chronic Metabolic Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029
6.3 By Type, Global Chronic Metabolic Disease Drug Consumption Value, 2018-2029
6.4 By Type, Global Chronic Metabolic Disease Drug Sales Quantity, 2018-2029
6.5 By Type, Global Chronic Metabolic Disease Drug Average Selling Price (ASP), 2018-2029
7 Sights by Application
7.1 Chronic Metabolic Disease Drug Segment by Application
7.1.1 Hospital
7.1.2 Clinic
7.1.3 Others
7.2 By Application, Global Chronic Metabolic Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029
7.3 By Application, Global Chronic Metabolic Disease Drug Consumption Value, 2018-2029
7.4 By Application, Global Chronic Metabolic Disease Drug Sales Quantity, 2018-2029
7.5 By Application, Global Chronic Metabolic Disease Drug Price, 2018-2029
8 Sales Sights by Region
8.1 By Region, Global Chronic Metabolic Disease Drug Consumption Value, 2018 VS 2022 VS 2029
8.2 By Region, Global Chronic Metabolic Disease Drug Consumption Value, 2018-2029
8.3 By Region, Global Chronic Metabolic Disease Drug Sales Quantity, 2018-2029
8.4 North America
8.4.1 North America Chronic Metabolic Disease Drug & Forecasts, 2018-2029
8.4.2 By Country, North America Chronic Metabolic Disease Drug Market Size Market Share
8.5 Europe
8.5.1 Europe Chronic Metabolic Disease Drug Market Size & Forecasts, 2018-2029
8.5.2 By Country, Europe Chronic Metabolic Disease Drug Market Size Market Share
8.6 Asia Pacific
8.6.1 Asia Pacific Chronic Metabolic Disease Drug Market Size & Forecasts, 2018-2029
8.6.2 By Country/Region, Asia Pacific Chronic Metabolic Disease Drug Market Size Market Share
8.7 South America
8.7.1 South America Chronic Metabolic Disease Drug Market Size & Forecasts, 2018-2029
8.7.2 By Country, South America Chronic Metabolic Disease Drug Market Size Market Share
8.8 Middle East & Africa
9 Sales Sights by Country Level
9.1 By Country, Global Chronic Metabolic Disease Drug Market Size & CAGR, 2018 VS 2022 VS 2029
9.2 By Country, Global Chronic Metabolic Disease Drug Consumption Value, 2018-2029
9.3 By Country, Global Chronic Metabolic Disease Drug Sales Quantity, 2018-2029
9.4 U.S.
9.4.1 U.S. Chronic Metabolic Disease Drug Market Size, 2018-2029
9.4.2 By Type, U.S. Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.4.3 By Application, U.S. Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.5 Europe
9.5.1 Europe Chronic Metabolic Disease Drug Market Size, 2018-2029
9.5.2 By Type, Europe Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.5.3 By Application, Europe Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.6 China
9.6.1 China Chronic Metabolic Disease Drug Market Size, 2018-2029
9.6.2 By Type, China Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.6.3 By Application, China Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.7 Japan
9.7.1 Japan Chronic Metabolic Disease Drug Market Size, 2018-2029
9.7.2 By Type, Japan Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.7.3 By Application, Japan Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.8 South Korea
9.8.1 South Korea Chronic Metabolic Disease Drug Market Size, 2018-2029
9.8.2 By Type, South Korea Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.8.3 By Application, South Korea Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.9 Southeast Asia
9.9.1 Southeast Asia Chronic Metabolic Disease Drug Market Size, 2018-2029
9.9.2 By Type, Southeast Asia Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.9.3 By Application, Southeast Asia Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.10 India
9.10.1 India Chronic Metabolic Disease Drug Market Size, 2018-2029
9.10.2 By Type, India Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.10.3 By Application, India Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.11 Middle East & Africa
9.11.1 Middle East & Africa Chronic Metabolic Disease Drug Market Size, 2018-2029
9.11.2 By Type, Middle East & Africa Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
9.11.3 By Application, Middle East & Africa Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
10 Manufacturers Profile
10.1 Novartis
10.1.1 Novartis Company Information, Head Office, Market Area, and Industry Position
10.1.2 Novartis Chronic Metabolic Disease Drug Models, Specifications, and Application
10.1.3 Novartis Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.1.4 Novartis Company Profile and Main Business
10.1.5 Novartis Recent Developments
10.2 Daiichi Sankyo
10.2.1 Daiichi Sankyo Company Information, Head Office, Market Area, and Industry Position
10.2.2 Daiichi Sankyo Chronic Metabolic Disease Drug Models, Specifications, and Application
10.2.3 Daiichi Sankyo Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.2.4 Daiichi Sankyo Company Profile and Main Business
10.2.5 Daiichi Sankyo Recent Developments
10.3 Actelion Pharmaceuticals
10.3.1 Actelion Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
10.3.2 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Models, Specifications, and Application
10.3.3 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.3.4 Actelion Pharmaceuticals Company Profile and Main Business
10.3.5 Actelion Pharmaceuticals Recent Developments
10.4 Boehringer Ingelheim
10.4.1 Boehringer Ingelheim Company Information, Head Office, Market Area, and Industry Position
10.4.2 Boehringer Ingelheim Chronic Metabolic Disease Drug Models, Specifications, and Application
10.4.3 Boehringer Ingelheim Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.4.4 Boehringer Ingelheim Company Profile and Main Business
10.4.5 Boehringer Ingelheim Recent Developments
10.5 Eli Lilly
10.5.1 Eli Lilly Company Information, Head Office, Market Area, and Industry Position
10.5.2 Eli Lilly Chronic Metabolic Disease Drug Models, Specifications, and Application
10.5.3 Eli Lilly Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.5.4 Eli Lilly Company Profile and Main Business
10.5.5 Eli Lilly Recent Developments
10.6 Fresenius Kabi
10.6.1 Fresenius Kabi Company Information, Head Office, Market Area, and Industry Position
10.6.2 Fresenius Kabi Chronic Metabolic Disease Drug Models, Specifications, and Application
10.6.3 Fresenius Kabi Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.6.4 Fresenius Kabi Company Profile and Main Business
10.6.5 Fresenius Kabi Recent Developments
10.7 Torrent Labs
10.7.1 Torrent Labs Company Information, Head Office, Market Area, and Industry Position
10.7.2 Torrent Labs Chronic Metabolic Disease Drug Models, Specifications, and Application
10.7.3 Torrent Labs Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.7.4 Torrent Labs Company Profile and Main Business
10.7.5 Torrent Labs Recent Developments
10.8 Pfizer
10.8.1 Pfizer Company Information, Head Office, Market Area, and Industry Position
10.8.2 Pfizer Chronic Metabolic Disease Drug Models, Specifications, and Application
10.8.3 Pfizer Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.8.4 Pfizer Company Profile and Main Business
10.8.5 Pfizer Recent Developments
10.9 Novo Nordisk
10.9.1 Novo Nordisk Company Information, Head Office, Market Area, and Industry Position
10.9.2 Novo Nordisk Chronic Metabolic Disease Drug Models, Specifications, and Application
10.9.3 Novo Nordisk Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.9.4 Novo Nordisk Company Profile and Main Business
10.9.5 Novo Nordisk Recent Developments
10.10 AstraZeneca plc
10.10.1 AstraZeneca plc Company Information, Head Office, Market Area, and Industry Position
10.10.2 AstraZeneca plc Chronic Metabolic Disease Drug Models, Specifications, and Application
10.10.3 AstraZeneca plc Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.10.4 AstraZeneca plc Company Profile and Main Business
10.10.5 AstraZeneca plc Recent Developments
10.11 Regeneron Pharmaceuticals
10.11.1 Regeneron Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
10.11.2 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Models, Specifications, and Application
10.11.3 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.11.4 Regeneron Pharmaceuticals Company Profile and Main Business
10.11.5 Regeneron Pharmaceuticals Recent Developments
10.12 GlaxoSmithKline plc
10.12.1 GlaxoSmithKline plc Company Information, Head Office, Market Area, and Industry Position
10.12.2 GlaxoSmithKline plc Chronic Metabolic Disease Drug Models, Specifications, and Application
10.12.3 GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.12.4 GlaxoSmithKline plc Company Profile and Main Business
10.12.5 GlaxoSmithKline plc Recent Developments
10.13 Merck & Co. Inc
10.13.1 Merck & Co. Inc Company Information, Head Office, Market Area, and Industry Position
10.13.2 Merck & Co. Inc Chronic Metabolic Disease Drug Models, Specifications, and Application
10.13.3 Merck & Co. Inc Chronic Metabolic Disease Drug Sales Quantity, Revenue, Price and Gross Margin, 2018-2023
10.13.4 Merck & Co. Inc Company Profile and Main Business
10.13.5 Merck & Co. Inc Recent Developments
11 Conclusion
12 Appendix
12.1 Research Methodology
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Market Estimation Model
12.4 Disclaimer
Table 1. Chronic Metabolic Disease Drug Consumption Value & CAGR: China VS Global, 2018-2029, US$ Million
Table 2. Chronic Metabolic Disease Drug Market Restraints
Table 3. Chronic Metabolic Disease Drug Market Trends
Table 4. Chronic Metabolic Disease Drug Industry Policy
Table 5. Global Chronic Metabolic Disease Drug Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022
Table 6. Global Chronic Metabolic Disease Drug Revenue Share by Company, 2018-2023, Ranked by Data of 2022
Table 7. Global Chronic Metabolic Disease Drug Sales Quantity by Company, (2018-2023) & (K Units), Ranked Based on Sales in 2022
Table 8. Global Chronic Metabolic Disease Drug Sales Quantity by Company, 2018-2023, Ranked by Data of 2022
Table 9. Global Chronic Metabolic Disease Drug Average Selling Price (ASP) by Company, (2018-2023) & (US$/Unit)
Table 10. Global Chronic Metabolic Disease Drug Manufacturers Market Concentration Ratio (CR3 and HHI)
Table 11. Global Chronic Metabolic Disease Drug Mergers & Acquisitions, Expansion Plans
Table 12. Global Chronic Metabolic Disease Drug Manufacturers Product Type
Table 13. Head Office and Chronic Metabolic Disease Drug Production Site of Key Manufacturer
Table 14. Chronic Metabolic Disease Drug Capacity of Major Manufacturers and Future Plan
Table 15. China Chronic Metabolic Disease Drug Revenue by Company, 2018-2023, US$ million, Ranked Based on Revenue in 2022
Table 16. China Chronic Metabolic Disease Drug Sales Quantity by Company, (2018-2023) & (K Units), Ranked Based on Sales in 2022
Table 17. China Chronic Metabolic Disease Drug Sales Quantity by Company, 2018-2023, Ranked by Data of 2022
Table 18. Global Chronic Metabolic Disease Drug Production & Forecast by Region, 2018 VS 2022 VS 2029, (K Units)
Table 19. Global Chronic Metabolic Disease Drug Production by Region, 2018-2023, (K Units)
Table 20. Global Chronic Metabolic Disease Drug Production Forecast by Region, 2024-2029, (K Units)
Table 21. Global Key Players of Chronic Metabolic Disease Drug Upstream (Raw Materials)
Table 22. Global Chronic Metabolic Disease Drug Typical Customers
Table 23. Chronic Metabolic Disease Drug Typical Distributors
Table 24. By Type, Global Chronic Metabolic Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 25. By Application, Global Chronic Metabolic Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 26. By Region, Global Chronic Metabolic Disease Drug Consumption Value, 2018 VS 2022 VS 2029, US$ Million
Table 27. By Region, Global Chronic Metabolic Disease Drug Consumption Value, 2018-2029, US$ Million
Table 28. By Region, Global Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Table 29. By Country, Global Chronic Metabolic Disease Drug Consumption Value & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 30. By Country, Global Chronic Metabolic Disease Drug Consumption Value, 2018-2029, US$ Million
Table 31. By Country, Global Chronic Metabolic Disease Drug Consumption Value Market Share, 2018-2029
Table 32. By Country, Global Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Table 33. By Country, Global Chronic Metabolic Disease Drug Sales Quantity Market Share, 2018-2029
Table 34. Novartis Company Information, Head Office, Market Area, and Industry Position
Table 35. Novartis Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 36. Novartis Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 37. Novartis Company Profile and Main Business
Table 38. Novartis Recent Developments
Table 39. Daiichi Sankyo Company Information, Head Office, Market Area, and Industry Position
Table 40. Daiichi Sankyo Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 41. Daiichi Sankyo Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 42. Daiichi Sankyo Company Profile and Main Business
Table 43. Daiichi Sankyo Recent Developments
Table 44. Actelion Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
Table 45. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 46. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 47. Actelion Pharmaceuticals Company Profile and Main Business
Table 48. Actelion Pharmaceuticals Recent Developments
Table 49. Boehringer Ingelheim Company Information, Head Office, Market Area, and Industry Position
Table 50. Boehringer Ingelheim Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 51. Boehringer Ingelheim Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 52. Boehringer Ingelheim Company Profile and Main Business
Table 53. Boehringer Ingelheim Recent Developments
Table 54. Eli Lilly Company Information, Head Office, Market Area, and Industry Position
Table 55. Eli Lilly Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 56. Eli Lilly Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 57. Eli Lilly Company Profile and Main Business
Table 58. Eli Lilly Recent Developments
Table 59. Fresenius Kabi Company Information, Head Office, Market Area, and Industry Position
Table 60. Fresenius Kabi Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 61. Fresenius Kabi Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 62. Fresenius Kabi Company Profile and Main Business
Table 63. Fresenius Kabi Recent Developments
Table 64. Torrent Labs Company Information, Head Office, Market Area, and Industry Position
Table 65. Torrent Labs Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 66. Torrent Labs Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 67. Torrent Labs Company Profile and Main Business
Table 68. Torrent Labs Recent Developments
Table 69. Pfizer Company Information, Head Office, Market Area, and Industry Position
Table 70. Pfizer Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 71. Pfizer Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 72. Pfizer Company Profile and Main Business
Table 73. Pfizer Recent Developments
Table 74. Novo Nordisk Company Information, Head Office, Market Area, and Industry Position
Table 75. Novo Nordisk Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 76. Novo Nordisk Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 77. Novo Nordisk Company Profile and Main Business
Table 78. Novo Nordisk Recent Developments
Table 79. AstraZeneca plc Company Information, Head Office, Market Area, and Industry Position
Table 80. AstraZeneca plc Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 81. AstraZeneca plc Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 82. AstraZeneca plc Company Profile and Main Business
Table 83. AstraZeneca plc Recent Developments
Table 84. Regeneron Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
Table 85. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 86. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 87. Regeneron Pharmaceuticals Company Profile and Main Business
Table 88. Regeneron Pharmaceuticals Recent Developments
Table 89. GlaxoSmithKline plc Company Information, Head Office, Market Area, and Industry Position
Table 90. GlaxoSmithKline plc Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 91. GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 92. GlaxoSmithKline plc Company Profile and Main Business
Table 93. GlaxoSmithKline plc Recent Developments
Table 94. Merck & Co. Inc Company Information, Head Office, Market Area, and Industry Position
Table 95. Merck & Co. Inc Chronic Metabolic Disease Drug Models, Specifications, and Application
Table 96. Merck & Co. Inc Chronic Metabolic Disease Drug Sales Quantity (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin, 2018-2023
Table 97. Merck & Co. Inc Company Profile and Main Business
Table 98. Merck & Co. Inc Recent Developments
List of Figures
Figure 1. Chronic Metabolic Disease Drug Picture
Figure 2. Global Chronic Metabolic Disease Drug Consumption Value, (US$ million) & (2018-2029)
Figure 3. Global Chronic Metabolic Disease Drug Sales Quantity, (K Units) & (2018-2029)
Figure 4. Global Chronic Metabolic Disease Drug Average Selling Price (ASP), (2018-2029) & (US$/Unit)
Figure 5. China Chronic Metabolic Disease Drug Consumption Value, (US$ million) & (2018-2029)
Figure 6. China Chronic Metabolic Disease Drug Sales Quantity (K Units) & (2018-2029)
Figure 7. China Chronic Metabolic Disease Drug Average Selling Price (ASP), (US$/Unit) & (2018-2029)
Figure 8. By Consumption Value, China Chronic Metabolic Disease Drug Market Share of Global, 2018-2029
Figure 9. By Sales Quantity, China Chronic Metabolic Disease Drug Market Share of Global, 2018-2029
Figure 10. Global Chronic Metabolic Disease Drug Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2022
Figure 11. China Chronic Metabolic Disease Drug Key Participants, Market Share, 2022
Figure 12. Global Chronic Metabolic Disease Drug Capacity, Production and Capacity Utilization, 2018-2029
Figure 13. Global Chronic Metabolic Disease Drug Capacity Market Share by Region, 2022 VS 2029
Figure 14. Global Chronic Metabolic Disease Drug Production Market Share & Forecast by Region, 2018-2029
Figure 15. Chronic Metabolic Disease Drug Industry Chain
Figure 16. Chronic Metabolic Disease Drug Procurement Model
Figure 17. Chronic Metabolic Disease Drug Sales Model
Figure 18. Chronic Metabolic Disease Drug Sales Channels, Direct Sales, and Distribution
Figure 19. Hypertension Drug
Figure 20. Hyperlipidemia Drug
Figure 21. High Blood Sugar Drug
Figure 22. High Uric Acid Drug
Figure 23. By Type, Global Chronic Metabolic Disease Drug Consumption Value, 2018-2029, US$ Million
Figure 24. By Type, Global Chronic Metabolic Disease Drug Consumption Value Market Share, 2018-2029
Figure 25. By Type, Global Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 26. By Type, Global Chronic Metabolic Disease Drug Sales Quantity Market Share, 2018-2029
Figure 27. By Type, Global Chronic Metabolic Disease Drug Average Selling Price (ASP), 2018-2029, (US$/Unit)
Figure 28. Hospital
Figure 29. Clinic
Figure 30. Others
Figure 31. By Application, Global Chronic Metabolic Disease Drug Consumption Value, 2018-2029, US$ Million
Figure 32. By Application, Global Chronic Metabolic Disease Drug Consumption Value Market Share, 2018-2029
Figure 33. By Application, Global Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 34. By Application, Global Chronic Metabolic Disease Drug Sales Quantity Market Share, 2018-2029
Figure 35. By Application, Global Chronic Metabolic Disease Drug Average Selling Price (ASP), 2018-2029, (US$/Unit)
Figure 36. By Region, Global Chronic Metabolic Disease Drug Consumption Value Market Share, 2018-2029
Figure 37. By Region, Global Chronic Metabolic Disease Drug Sales Quantity Market Share, 2018-2029
Figure 38. North America Chronic Metabolic Disease Drug Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 39. By Country, North America Chronic Metabolic Disease Drug Consumption Value Market Share, 2022
Figure 40. Europe Chronic Metabolic Disease Drug Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 41. By Country, Europe Chronic Metabolic Disease Drug Consumption Value Market Share, 2022
Figure 42. Asia Pacific Chronic Metabolic Disease Drug Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 43. By Country/Region, Asia Pacific Chronic Metabolic Disease Drug Consumption Value Market Share, 2022
Figure 44. South America Chronic Metabolic Disease Drug Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 45. By Country, South America Chronic Metabolic Disease Drug Consumption Value Market Share, 2022
Figure 46. Middle East & Africa Chronic Metabolic Disease Drug Consumption Value & Forecasts, 2018-2029, US$ Million
Figure 47. U.S. Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 48. By Type, U.S. Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 49. By Application, U.S. Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 50. Europe Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 51. By Type, Europe Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 52. By Application, Europe Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 53. China Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 54. By Type, China Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 55. By Application, China Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 56. Japan Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 57. By Type, Japan Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 58. By Application, Japan Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 59. South Korea Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 60. By Type, South Korea Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 61. By Application, South Korea Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 62. Southeast Asia Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 63. By Type, Southeast Asia Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 64. By Application, Southeast Asia Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 65. India Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 66. By Type, India Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 67. By Application, India Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 68. Middle East & Africa Chronic Metabolic Disease Drug Sales Quantity, 2018-2029, (K Units)
Figure 69. By Type, Middle East & Africa Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 70. By Application, Middle East & Africa Chronic Metabolic Disease Drug Sales Quantity Market Share, 2022 VS 2029
Figure 71. Research Methodology
Figure 72. Breakdown of Primary Interviews
Figure 73. Bottom-up and Top-down Approaches
Figure 74. Top-down Approaches
Methodology/Research Approach
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Research Programs/Design
| Historical Data (2015-2019) |
|
|
| Influencing Factors |
|
|
| Market Forecast (2021-2026) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).
The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.
Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report
The following figure shows an illustrative representation of the overall market size estimation process used for this study.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Data Source
Secondary Sources
Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.
Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
Key Executives Interviewed
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|